Gold stocks to beat market volatility
Gold stocks to beat market volatility
Lens over SUDA’s Operational Highlights in 1H FY20

Lens over SUDA’s Operational Highlights in 1H FY20

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to focus on attr...

Glance at BPH Energy’s Operational Performance in 1H FY20

Glance at BPH Energy’s Operational Performance in 1H FY20

  • Mar 02, 2020
  • Team Kalkine

Just a few days after announcing its proposal to implement a 1 for 10 share consolidation, Australia’s diversified player BPH Energy Limited (ASX:BPH) has now declared its half-year results for the period ended 31st December 2019. With a focus ...

Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued

Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued

  • Mar 02, 2020
  • Team Kalkine

Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front line chemo...

Cast an Eye Over Imugene’s Impressive Achievements in 1H FY20

Cast an Eye Over Imugene’s Impressive Achievements in 1H FY20

  • Feb 28, 2020
  • Team Kalkine

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released another set of robust operational results for the half-year ended 31st December 2019. It was certainly a remarkable half-year for the biotech player,...

Noxopharm’s Veyonda® Granted IND for Sarcoma Patients.

Noxopharm’s Veyonda® Granted IND for Sarcoma Patients.

  • Feb 25, 2020
  • Team Kalkine

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

Mapping Prescient’s PTX-200 Progress

Mapping Prescient’s PTX-200 Progress

  • Feb 19, 2020
  • Team Kalkine

Known for developing breakthrough personalised medicines using an approach to address specific mutations that drive cancer, thereby providing resistance to front line chemotherapy,  Prescient Therapeutics Limited (ASX: PTX) has been gaining...

Healthcare Stocks in Penny Space- IPD, ANP

Healthcare Stocks in Penny Space- IPD, ANP

  • Feb 13, 2020
  • Team Kalkine

 Healthcare is a lucrative and dynamic sector for investors, and amid ambiguity and fluctuating stock market environment, Australia’s healthcare system stands out as one of the top sectors for investment purpose. Investment in healthcare s...

Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer

Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer

  • Feb 10, 2020
  • Team Kalkine

Noxopharm Limited (ASX:NOX), an Australian clinical stage biotechnology company with its focus on oncology, is known for developing a novel, potentially transformative and industry disruptive cancer drug treatment using its lead candidate, Veyonda&re...

A Flip Through Imugene’s December 2019 Quarterly 4C Report

A Flip Through Imugene’s December 2019 Quarterly 4C Report

  • Feb 05, 2020
  • Team Kalkine

Australia-headquartered clinical stage immuno-oncology player, Imugene Limited (ASX:IMU) has recently released its Quarterly 4C report on the ASX, highlighting its key activities undertaken during December 2019 quarter. Imugene continued to focus on ...

SUDA Delivered Strong Performance in 2Q FY20, A Glimpse of Operational Highlights

SUDA Delivered Strong Performance in 2Q FY20, A Glimpse of Operational Highlights

  • Feb 05, 2020
  • Team Kalkine

Continuing its practice of making robust quarterly progress, the oro-mucosal drug delivery player of Australia, SUDA Pharmaceuticals Limited (ASX: SUD) is out with another solid quarterly report for the December 2019 quarter. SUDA is a world leader ...

Register Now

Get a call back now to get stock recommendations